Ironwood Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Ironwood Pharmaceuticals is Tom McCourt, benoemd in Mar2021, heeft een ambtstermijn van 3.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.58M, bestaande uit 11% salaris en 89% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.32% van de aandelen van het bedrijf, ter waarde $ 1.76M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 5.6 jaar.
Belangrijke informatie
Tom McCourt
Algemeen directeur
US$7.6m
Totale compensatie
| Percentage CEO-salaris | 11.0% |
| Dienstverband CEO | 3.7yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 3yrs |
| Gemiddelde ambtstermijn bestuur | 5.6yrs |
Recente managementupdates
Recent updates
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
Oct 24
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Aug 16Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
Jun 27Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Jun 20Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$2m |
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | -US$1b |
| Dec 31 2023 | US$8m | US$834k | -US$1b |
| Sep 30 2023 | n/a | n/a | -US$952m |
| Jun 30 2023 | n/a | n/a | -US$917m |
| Mar 31 2023 | n/a | n/a | US$182m |
| Dec 31 2022 | US$8m | US$805k | US$175m |
| Sep 30 2022 | n/a | n/a | US$168m |
| Jun 30 2022 | n/a | n/a | US$173m |
| Mar 31 2022 | n/a | n/a | US$527m |
| Dec 31 2021 | US$9m | US$732k | US$528m |
| Sep 30 2021 | n/a | n/a | US$530m |
| Jun 30 2021 | n/a | n/a | US$509m |
| Mar 31 2021 | n/a | n/a | US$143m |
| Dec 31 2020 | US$3m | US$576k | US$106m |
| Sep 30 2020 | n/a | n/a | US$111m |
| Jun 30 2020 | n/a | n/a | US$97m |
| Mar 31 2020 | n/a | n/a | US$84m |
| Dec 31 2019 | US$5m | US$511k | US$59m |
| Sep 30 2019 | n/a | n/a | US$19m |
| Jun 30 2019 | n/a | n/a | -US$153m |
| Mar 31 2019 | n/a | n/a | -US$173m |
| Dec 31 2018 | US$2m | US$465k | -US$194m |
| Sep 30 2018 | n/a | n/a | -US$190m |
| Jun 30 2018 | n/a | n/a | -US$71m |
| Mar 31 2018 | n/a | n/a | -US$108m |
| Dec 31 2017 | US$2m | US$450k | -US$55m |
Compensatie versus markt: De totale vergoeding ($USD 7.58M ) Tom } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.16M ).
Compensatie versus inkomsten: De vergoeding van Tom is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Tom McCourt (67 yo)
3.7yrs
Tenure
US$7,583,270
Compensatie
Mr. Thomas A. McCourt, also known as Tom, serves as Director at Pliant Therapeutics, Inc. since March 08, 2023. He serves as Chief Executive Officer and Director of Ironwood Pharmaceuticals, Inc. since Jun...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 3.7yrs | US$7.58m | 0.32% $ 1.8m | |
| Senior VP | 2.9yrs | US$2.76m | 0.091% $ 502.5k | |
| Senior VP | 3.3yrs | US$2.44m | 0.079% $ 437.5k | |
| Chief Medical Officer | 5.8yrs | US$2.60m | 0.16% $ 865.5k | |
| Senior VP & Chief Business Officer | 2.8yrs | US$2.67m | 0.10% $ 563.1k | |
| Corporate Controller & Principal Accounting Officer | 5.6yrs | geen gegevens | 0.042% $ 233.7k | |
| VP & Global Head of Technical Operations | less than a year | geen gegevens | geen gegevens | |
| Vice President of Strategic Finance & Investor Relations | no data | geen gegevens | geen gegevens | |
| VP of Corporate Communications & Media Relations | 2.8yrs | geen gegevens | geen gegevens | |
| Vice President of Sales & Sales Excellence | 3.2yrs | geen gegevens | geen gegevens | |
| VP & Head of Clinical Development | 2.2yrs | geen gegevens | geen gegevens | |
| Director of Investor Relations | no data | geen gegevens | geen gegevens |
3.0yrs
Gemiddelde duur
47yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van IRWD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 3.4yrs | US$7.58m | 0.32% $ 1.8m | |
| Independent Director | 3.9yrs | US$300.71k | 0.079% $ 435.3k | |
| Member of Pharmaceuticals Advisory Committee | no data | geen gegevens | geen gegevens | |
| Independent Director | 4yrs | US$300.69k | 0.095% $ 523.2k | |
| Independent Director | 5.6yrs | US$300.71k | 0.36% $ 2.0m | |
| Independent Director | 8.6yrs | US$310.71k | 0.12% $ 647.5k | |
| Member of Pharmaceutical Advisory Committee | 7.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.6yrs | US$310.69k | 0.046% $ 250.9k | |
| Independent Chairman of the Board | 10.8yrs | US$335.71k | 0.10% $ 563.6k | |
| Independent Director | 5.6yrs | US$300.71k | 0.076% $ 415.8k | |
| Independent Director | 5.6yrs | US$305.71k | 0.091% $ 500.0k |
5.6yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van IRWD wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).